Carmot Therapeutics, Inc.
2 registered trials on this site, 0 active. This page lists the trials this organization is registered as lead sponsor of, for the compounds covered on PeptideBlog.net. It is a registry listing, not an assessment of the company or its products.
Compounds covered
Registered trials
| Trial | Compound | Phase | Status | Sponsor | Enrolled | Primary completion | Registry updated |
|---|---|---|---|---|---|---|---|
| A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus NCT06628362 | Enicepatide (CT-388) | Phase 2 | Active not recruiting | Carmot Therapeutics, Inc. | 447 | May 29, 2026 | Jun 24, 2026 |
| A Study of Enicepatide (CT-388) in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity NCT06525935 | Enicepatide (CT-388) | Phase 2 | Completed | Carmot Therapeutics, Inc. | 469 | Dec 8, 2025 | Apr 17, 2026 |
Data: ClinicalTrials.gov, U.S. National Library of Medicine. See the full trial tracker.
